Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin

NCT01532544 Phase 2 TERMINATED

This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating the safety and efficacy of co-administration of Iloprost and escalating doses of Eptifibatide for continuous intravenous infusion in totally 36 patients.

Details

Lead sponsor	Thrombologic ApS
Phase	Phase 2
Status	TERMINATED
Enrolment	5
Start date	2012-06
Completion	2014-03

Conditions

• Pneumonia

Interventions

• Ilomedin and Integrilin
• low molecular weight heparin.

Primary outcomes

• Change in platelet count from baseline to 72 hours post treatment — 11 bloodsamples over 7 days
  Will be from pre-study drug administration until 7 days

Countries

Denmark, Finland